Sjogren’s Treatment Report

www.SjogrensTreatmentReport.com

Phase 1

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr

https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome Phase Ib-IIa Placebo-Controlled Clinical Trial and Associated Mechanistic Studies

DESCRIPTION:
Condition:   Sjogren’s Syndrome
Interventions:   Drug: tofacitinib;   Other: Placebo
Sponsor:   National Institute of Dental and Craniofacial Research (NIDCR)
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04496960

FIRST POSTED:
Tue, 04 Aug 2020 12:00:00 EDT

LAST UPDATE POSTED:
08/04/20 07:19AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst

Fecal Microbial Transplant (FMT) for Sjogren’s Syndrome [Completed]

https://www.clinicaltrials.gov/ct2/show/NCT03926286?type=Intr&cond=Sjogren%27s+Syndrome&sort=nwst&draw=2&rank=9

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

Study Description
Go to sections
Brief Summary:
This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters.

Condition or disease Intervention/treatment Phase
Sjogren’s Syndrome
Drug: FMP-30
Phase 1

Study Design
Go to sections
Study Type : Interventional
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fecal Microbial Transplant for Sjogrens Syndrome
Actual Study Start Date : April 15, 2019
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : December 1, 2021

Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome

DESCRIPTION:
Condition:   Primary Sjögren Syndrome
Intervention:   Drug: Ustekinumab
Sponsor:   University of Rochester
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04093531

FIRST POSTED:
Wed, 18 Sep 2019 12:00:00 EDT

LAST UPDATE POSTED:
10/22/19 07:00AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

Back to top